InventisBio opens Phase 1 renal-impairment PK study of D-2570 in China
The trial will compare D-2570 exposure in participants with impaired kidney function against normal renal function, standard groundwork before any dose-adjustment or filing decision.
Executive Summary
- InventisBio has registered a Phase 1 pharmacokinetic study designed to compare how D-2570 behaves in people with impaired kidney function against those with normal renal function.
- The design is a dose-adjustment groundwork study, not an efficacy trial, and its primary measure is drug exposure rather than clinical response.
- InventisBio brings a completion record across its prior trial portfolio, a base that gives the study's timeline some operational credibility.
- The renal-impairment pharmacokinetic space is populated by several sponsors each testing their own distinct drug, none of which shares a disclosed target or mechanism with D-2570.
The study
InventisBio Co., Ltd is set to begin a Phase 1 trial, registered as NCT07715175 and internally designated D2570-107, testing D-2570 in participants with renal impairment against those with normal renal function. The trial is not yet recruiting, with a planned start date of August 9, 2026, and a primary completion date of November 21, 2026. It will enroll an anticipated 40 participants across four arms in China, using an open-label, non-randomized design. The primary outcome measure is plasma concentration of D-2570 through approximately day nine of the study, with adverse-event monitoring as a secondary measure. NCT07715175A Pharmacokinetic Study of D-2570 in Trial Participants With Renal Impairment Versus Normal Renal FunctionNCT07715175
Why it matters
Pharmacokinetic bridging studies like this one exist to answer a narrow question: does reduced kidney function change how a drug is absorbed, distributed, or cleared, and if so, does the dose need adjustment for that population. The trial is not registrational and carries no efficacy endpoint. Its information value sits entirely in the exposure comparison between the renal-impairment and normal-function groups; a result showing meaningfully altered plasma concentrations in impaired participants would inform how, or whether, D-2570 can be dosed in that population going forward. NCT07715175A Pharmacokinetic Study of D-2570 in Trial Participants With Renal Impairment Versus Normal Renal FunctionNCT07715175
Sponsor and pipeline
InventisBio has completed 17 of 18 prior trials it has run, with one terminated, a track record that gives this study's guided timeline some operational grounding. Across its broader portfolio, the sponsor currently has 8 trials recruiting, 5 active but not recruiting, and 1 not yet recruiting, alongside the 17 completed and 1 terminated. This is InventisBio's only registered trial for D-2570, meaning the drug's clinical program in renal impairment rests on this single study for now. A+1A Pharmacokinetic Study of D-2570 in Trial Participants With Renal Impairment Versus Normal Renal FunctionJul 20, 2026A Pharmacokinetic Study of D-2570 in Trial Participants With Renal Impairment Versus Normal Renal FunctionNCT07715175
The competitive field
Renal-impairment pharmacokinetic studies are a recurring, non-competitive category: sponsors run them to characterize their own drugs, not to outcompete rivals on a shared endpoint. Several other sponsors have active or recent Phase 1 renal-impairment pharmacokinetic trials, including Pfizer's PF-07328948 study, Incyte Corporation's INCB123667 study, and Eli Lilly and Company's eloralintide study. None of these shares a disclosed target, mechanism, or modality with D-2570, and each is testing its own distinct molecule under its own development program, so this trial sits within a landscape of parallel, mechanism-independent pharmacokinetic studies rather than a field of direct rivals.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.